Mycobacterium Ulcerans Treatment – Can Antibiotic Duration Be Reduced in Selected Patients?

• Raquel Cowan ,

  * E-mail: raquel@arqmedical.com.au

  Affiliation Department of Infectious Diseases, Barwon Health, Geelong, Australia

  ⨯
• Eugene Athan,

  Affiliation Department of Infectious Diseases, Barwon Health, Geelong, Australia

  ⨯
• N. Deborah Friedman,

  Affiliation Department of Infectious Diseases, Barwon Health, Geelong, Australia

  ⨯
• Andrew J. Hughes,

  Affiliation Department of Infectious Diseases, Barwon Health, Geelong, Australia

  ⨯
• Anthony McDonald,

  Affiliation Department of Plastic Surgery, Barwon Health, Geelong, Australia

  ⨯
• Peter Callan,

  Affiliation Department of Plastic Surgery, Barwon Health, Geelong, Australia

  ⨯
• Janet Fyfe,

  Affiliations Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia, WHO Collaborating Centre for Mycobacterium ulcerans, VIDRL, Melbourne, Australia

  ⨯
• Daniel P. O’Brien

  Affiliations Department of Infectious Diseases, Barwon Health, Geelong, Australia, Manson Unit, Mèdecins Sans Frontières, London, United Kingdom, Department of Medicine and Infectious Diseases, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia

  ⨯